Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.

BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increa...

Повний опис

Бібліографічні деталі
Автори: Tinsley, J, Fairclough, R, Storer, R, Wilkes, F, Potter, A, Squire, SE, Powell, D, Cozzoli, A, Capogrosso, R, Lambert, A, Wilson, F, Wren, S, De Luca, A, Davies, K
Формат: Journal article
Мова:English
Опубліковано: Public Library of Science 2011
_version_ 1826303601843109888
author Tinsley, J
Fairclough, R
Storer, R
Wilkes, F
Potter, A
Squire, SE
Powell, D
Cozzoli, A
Capogrosso, R
Lambert, A
Wilson, F
Wren, S
De Luca, A
Davies, K
author_facet Tinsley, J
Fairclough, R
Storer, R
Wilkes, F
Potter, A
Squire, SE
Powell, D
Cozzoli, A
Capogrosso, R
Lambert, A
Wilson, F
Wren, S
De Luca, A
Davies, K
author_sort Tinsley, J
collection OXFORD
description BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS: We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE: This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients.
first_indexed 2024-03-07T06:05:12Z
format Journal article
id oxford-uuid:ed989d83-882f-490c-b5ff-d650858e7db3
institution University of Oxford
language English
last_indexed 2024-03-07T06:05:12Z
publishDate 2011
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:ed989d83-882f-490c-b5ff-d650858e7db32022-03-27T11:26:16ZDaily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ed989d83-882f-490c-b5ff-d650858e7db3EnglishSymplectic Elements at OxfordPublic Library of Science2011Tinsley, JFairclough, RStorer, RWilkes, FPotter, ASquire, SEPowell, DCozzoli, ACapogrosso, RLambert, AWilson, FWren, SDe Luca, ADavies, KBACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS: We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE: This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients.
spellingShingle Tinsley, J
Fairclough, R
Storer, R
Wilkes, F
Potter, A
Squire, SE
Powell, D
Cozzoli, A
Capogrosso, R
Lambert, A
Wilson, F
Wren, S
De Luca, A
Davies, K
Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
title Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
title_full Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
title_fullStr Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
title_full_unstemmed Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
title_short Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
title_sort daily treatment with smtc1100 a novel small molecule utrophin upregulator dramatically reduces the dystrophic symptoms in the mdx mouse
work_keys_str_mv AT tinsleyj dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT faircloughr dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT storerr dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT wilkesf dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT pottera dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT squirese dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT powelld dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT cozzolia dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT capogrossor dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT lamberta dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT wilsonf dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT wrens dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT delucaa dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse
AT daviesk dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse